AcelRx Pharmaceuticals, Inc. — Q2 2016 Form 10-Q
Entity note: The request metadata names TALPHERA, INC., but the supplied filing is for AcelRx Pharmaceuticals, Inc. This summary reflects the filing provided. Reporting period: quarter and six months ended June 30, 2016; unaudited. Dollar amounts below are in millions unless stated otherwise.
Business context and reporting period
AcelRx is a specialty pharmaceutical company developing acute-pain therapies, principally ARX-04 and Zalviso, both based on sublingual sufentanil. Zalviso was approved in Europe and commercially launched by partner Grünenthal in April 2016; U.S. approval remains pending. ARX-04 is investigational, with the company targeting a U.S. NDA submission by year-end 2016, subject to trial results.
Financial performance and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Total revenue | $4.5 | $1.9 | $7.6 | $2.1 |
| Operating costs and expenses | $12.9 | $10.0 | $24.4 | $21.6 |
| Operating loss | $(8.3) | $(8.1) | $(16.8) | $(19.5) |
| Net loss | $(11.1) | $(8.9) | $(22.1) | $(18.9) |
| Basic and diluted loss per share | $(0.24) | $(0.20) | $(0.49) | $(0.43) basic; $(0.47) diluted |
| Net cash used in operating activities | Not presented by quarter | $(14.5) | $(21.4) |
- Q2 revenue comprised $3.2 million of U.S. Department of Defense (DoD) contract revenue and $1.3 million of Grünenthal collaboration revenue. First-half amounts were $4.4 million and $3.1 million, respectively. Zalviso product deliveries to Grünenthal contributed $2.7 million of first-half collaboration revenue.
- Q2 net loss widened year over year despite higher revenue, reflecting higher operating costs and $2.3 million of non-cash interest expense on the royalty monetization liability. First-half net loss also increased; lower R&D expense was more than offset by cost of goods sold and non-cash royalty-related interest expense.
- Gross margin is not separately stated in the filing. Cost of goods sold was $3.0 million for Q2 and $6.6 million for the first half, including manufacturing costs for Zalviso supply.
- Cash, cash equivalents and short-term investments were $98.8 million at June 30, versus $113.5 million at December 31, 2015. Cash and cash equivalents alone were $97.8 million. First-half operating cash use improved to $14.5 million from $21.4 million.
- Total assets were $113.6 million; total liabilities were $100.1 million; stockholders’ equity was $13.5 million. Hercules debt was $21.3 million, including $13.9 million classified as current. The royalty-sale liability to PDL was $68.1 million, of which $0.4 million was current.
- Management said existing capital resources were expected to fund operations through at least the first half of 2017, but not through the point of self-sustaining revenue. The company had a $40 million ATM equity sales agreement; it had sold no shares under it by June 30.
Material changes versus the prior comparable period
- Q2 revenue rose to $4.5 million from $1.9 million, mainly reflecting DoD-funded ARX-04 work and initial Zalviso product sales to Grünenthal. First-half revenue increased to $7.6 million from $2.1 million.
- Q2 net loss increased to $11.1 million from $8.9 million; first-half net loss increased to $22.1 million from $18.9 million. First-half operating loss narrowed, but total net loss rose due in part to $4.5 million in non-cash interest expense related to the PDL royalty monetization.
- First-half R&D expense declined 23% to $10.5 million, with lower Zalviso and overhead spending partly offset by higher ARX-04 spending. Q2 G&A expense rose 32% to $3.6 million, primarily due to ARX-04 market research and other costs.
- Cash and investments declined $14.7 million from year-end. The royalty-sale liability increased as the company accrued non-cash interest expense.
Outlook, commentary and principal risks
- ARX-04: Phase 3 SAP302 and SAP303 had completed last-patient visits; results were being analyzed, with top-line data expected in Q3 2016. The company planned an NDA by year-end, contingent on successful results. DoD funding of up to $17 million supports development; the contract was extended to March 2017 without increasing its total value.
- Zalviso: The FDA’s 2014 Complete Response Letter requires device-related remediation and an additional clinical study, IAP312. A September 2016 start was only an estimate; supply readiness and site preparation could delay initiation. Failure to start before year-end could leave insufficient resources to complete the study and resubmit the NDA.
- European commercialization and supply: Grünenthal was running limited hospital pilots in Germany and had initiated sales in France, the U.K., Italy and Belgium. Wider German availability depended on pilot success. Zalviso cartridge deliveries from Patheon were behind schedule, potentially affecting partner sales and launch timing.
- Royalty monetization: PDL received 75% of European royalties and 80% of the first four commercial milestones, subject to a $195 million cap. The company estimated approximately $9.4 million of non-cash interest expense for 2016, including $4.9 million in the second half.
- Funding and operating risks: The company reported recurring losses and negative operating cash flows. Additional capital may be needed; equity financing could dilute shareholders. Other key risks include regulatory uncertainty, clinical-trial outcomes and timing, manufacturing and supply constraints, reliance on Grünenthal, debt service and the possibility that FDA requirements exceed available resources.
- Management reported disclosure controls and procedures were effective as of June 30, 2016, with no material change in internal control over financial reporting during the quarter. No material contractual-obligation changes were reported; no off-balance-sheet arrangements were identified. The filing states there were no legal proceedings requiring disclosure, while describing a securities class action dismissed with prejudice in January 2016.
Important facts for investors to verify
- Confirm the issuer: the supplied document is AcelRx Pharmaceuticals, Inc., not TALPHERA, INC.
- Review SAP302/SAP303 results and whether they supported the planned ARX-04 NDA timing and scope.
- Track IAP312 initiation, clinical supply readiness, enrollment and the path to a Zalviso NDA resubmission.
- Monitor Patheon’s cartridge delivery performance and Grünenthal’s hospital pilots, country launches and resulting sales or royalties.
- Assess cash burn, runway assumptions, DoD reimbursements, the $40 million ATM facility and potential dilution or other financing needs.
- Reconcile debt maturity and repayment obligations with the PDL royalty liability, including the effect of the royalty cap and projected non-cash interest expense.